Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VSTM
VERASTEM, INC.
NASDAQ
$7.22
▼ DOWN 2.17% (-0.16)

KEY STATISTICS

Market Cap$634.45 M
52w High$11.25
52w Low$3.43
Dividend Yield—
Frequency—
P/E-2.89
Volume1.08M
Shares Out.87.87M

COMPANY

LEADERSHIP

Daniel W. Paterson
CHIEF EXECUTIVE
Daniel W. Paterson

COMPENSATION 2026

Salary$674,000
Stock Awards$1,161,661
Incentive Plan Pay$489,324
All Other Comp.$24,990
Total$2,349,975

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 27, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
102

PRICE TARGET

Target High$18.00
Target Low$8.00
Target Median$13.50
Target Consensus$13.83

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$29.13M
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2023-06-01Reverse1:12

PRICE

$7.22 ▼ DOWN 2.17% (−$0.16)
OVERLAYS
$7.20$7.24$7.28$7.329:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM7.22

About Verastem, Inc.

https://www.verastem.com ↗

Verastem, Inc. is a biopharmaceutical company developing cancer treatments like VS-6766, a RAF/MEK inhibitor, through clinical trials and collaborations with Pfizer, Chugai, and Amgen.

INDUSTRY

Biotechnology

A PRODUCT VERASTEM, INC. IS KNOWN FOR

AVMAPKI™ FAKZYNJA™ CO-PACK
AVMAPKI™ FAKZYNJA™ CO-PACK

Verastem Oncology's first FDA-approved targeted combination therapy of avutometinib and defactinib treats adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

COMPETITORS

COMPETITOR
AMGN COMPARE
BMY COMPARE
NVS COMPARE
PFE COMPARE
RVMD COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Government rebates and other incentives$2.04M $2.02M ▼$3.12M ▲$6.13M ▲
Trade discounts and allowances$467K $392K ▼$524K ▲$1.21M ▲
Returns$165K $185K ▲$598K ▲$602K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
74
LISTED HERE
14
RANKED BY POSITION SIZE
XBI
0.22% · 3.6M
VTI
0.00% · 2.8M
IWM
0.02% · 2.0M
FESM
0.09% · 790.5K
BBP
2.21% · 357.1K
LABU
0.15% · 131.4K
DFMC
0.01% · 83.5K
PRFZ
0.02% · 81.7K
XRSU.L
0.02% · 73.1K
RSSL
0.02% · 37.8K
URTY
0.01% · 3.2K
VETS
0.03% · 1.7K
RESM
0.02% · 155
AVTM
0.00% · 107

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.93%
HOLDERS
248
TOP 12 OF 248 · RANKED BY POSITION SIZE
Blackrock, Inc.
9.2M sh · $35.12M
Armistice Capital, LLC
7.0M sh · $26.83M
Rtw Investments, LP
6.6M sh · $25.35M
Deep Track Capital, LP
5.7M sh · $21.93M
State Street Corp
5.1M sh · $19.61M
Vanguard Group Inc
4.2M sh · $32.06M
Balyasny Asset Management L.P.
4.1M sh · $36.62M
Logos Global Management LP
4.0M sh · $35.76M
Rosalind Advisors, Inc.
4.0M sh · $15.23M
Polar Capital Holdings Plc
3.9M sh · $30.3M
Point72 Asset Management, L.P.
3.9M sh · $34.25M
Nantahala Capital Management, LLC
3.6M sh · $13.69M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Paterson Dan
Sale · 1.3K shares
2026-08-03
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Paterson Dan
Sale · 20.9K shares
2026-06-22
★
OFFICER: CHIEF FINANCIAL OFFICER
Calkins Daniel
Sale · 4.0K shares
2026-06-22
★
OFFICER: CHIEF FINANCIAL OFFICER
Calkins Daniel
Sale · 57 shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 2
6 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM Guggenheim BUY RBC Capital OUTPERFORM BTIG BUY HC Wainwright & Co. BUY Jefferies BUY

SECTORS PEERS

PEERPRICE
ABSI$8.71COMPARE
MLTX$14.99COMPARE
CRVS$14.16COMPARE
OLMA$10.27COMPARE
FDMT$14.67COMPARE
RGNX$9.66COMPARE
PRTA$9.33COMPARE
GOSS$0.17COMPARE